Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR

Revenue Cycle Management Market worth $84.1 billion | MarketsandMarkets

Published

on

revenue-cycle-management-market-worth-$84.1-billion-|-marketsandmarkets

CHICAGO, June 30, 2023 /PRNewswire/ — In the near future, the revenue cycle management (RCM) industry is expected to undergo significant transformation and growth. Advancements in technology, such as artificial intelligence and machine learning, will drive automation and optimization of RCM processes, reducing administrative costs and expediting revenue cycles. Data analytics will play a crucial role in identifying revenue leakage and improving financial outcomes. Moreover, there will be a greater emphasis on patient experience, with transparent pricing, cost estimates, and convenient payment options becoming integral to RCM practices. Compliance with evolving regulatory requirements will be a key focus, leading to increased demand for specialized RCM expertise. Outsourcing and strategic partnerships will continue to be prevalent, allowing healthcare organizations to leverage the expertise and scalability of RCM vendors. As the industry adapts to evolving payment models, such as value-based care, RCM processes will need to align with new reimbursement methodologies. Overall, the future of the RCM industry holds immense potential for innovation, efficiency, and improved financial outcomes for healthcare organizations.

Revenue Cycle Management Market in terms of revenue was estimated to be worth $49.6 billion in 2023 and is poised to reach $84.1 billion by 2028, growing at a CAGR of 11.1% from 2023 to 2028 according to a new report by MarketsandMarkets™. The shift from fee-for-service to value-based reimbursement models is transforming the RCM market. Value-based reimbursement models are based on patient outcomes rather than the volume of treatments rendered to patients. Value-based reimbursement models have enhanced patient experience and facilitated financial workflows for providers. This has positively impacted the RCM market growth to a certain extent. Also, growing regulatory requirements & government initiatives are expected to drive demand of the RCM market during the forecast period.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153900104

Browse in-depth TOC on “Revenue Cycle Management Market”

282 – Tables
40 – Figures
275 – Pages

Revenue Cycle Management Market Scope:

Report Coverage

Details

Market Revenue in 2023

$49.6 billion

Estimated Value by 2028

$84.1 billion

Growth Rate

Poised to grow at a CAGR of 11.1%

Market Size Available for

2021–2028

Forecast Period

2023–2028

Forecast Units

Value (USD Billion)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Segments Covered

Product & services, delivery mode, end user and region

Geographies Covered

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

Report Highlights

Updated financial information / product portfolio of players

Key Market Opportunities

Growing demand for AI & cloud-based deployment

Key Market Drivers

Growing need to manage unstructured healthcare data

By product & services segment, the outsourcing services segment is expected to grow at the highest growth rate during the forecast period.

The outsourced services segment is anticipated to expand at a considerable CAGR among the product & service categories throughout the forecast period. This can be attributed to its ability to optimize revenue cycle operations through the utilization of specialized resources and expertise from third-party providers. By doing so, healthcare organizations can focus on their core competencies, achieve cost reductions, and enhance operational efficiency. Furthermore, outsourcing services grant access to advanced technology platforms, enabling seamless integration, streamlined workflows, and robust data analytics capabilities. With scalability and adaptability, outsourcing services drive revenue cycle management advancements, bolster financial stability, and elevate overall performance for healthcare providers.

By delivery mode, the on-premise segment is expected to account for the largest revenue cycle management market share.

In 2022, the on-premise segment held the largest market share for revenue cycle management globally. The significant market share of this segment can be attributed to the security and data safety features possessed by on-premise deployment. Easy data access within the interdependent facilities of a healthcare setting has further elevated the market share.

By end user, the healthcare providers segment is expected to account for the largest share of the revenue cycle management market.

Healthcare payers and providers are the two market segments for revenue cycle management based on end users. RCM offers numerous benefits for healthcare providers, helping them optimize financial performance, improve operational efficiency, and enhance the overall patient experience. These factors have elevated the adoption of RCM solutions amongst healthcare providers, thus, positively impacting the market growth.

North America dominates the revenue cycle management market during the forecast period.

In 2022, North America held the largest market share for revenue cycle management. The large share of this region can be attributed to several factors, including strict regulations, an increase in the number of claims denials, well-established government payers and high numbers of private healthcare payers, and a sizable number of healthcare IT companies.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=153900104

Revenue Cycle Management Market Dynamics:

Drivers:

  1. Growing need to manage unstructured healthcare data

Restraints:

  1. Deployment costs include licensing and subscription costs

Opportunities:

  1. Growing demand for AI & cloud-based deployment

Challenges:

  1. Issues related to data security and confidentiality

Key Market Players:

R1 RCM (US), Oracle (US), Optum (US) are the leading players in the market. Other players include McKesson Corporation (US), Change Healthcare (US), 3M (US), Experian plc (Ireland), Conifer Health Solutions (US), Veradigm (US), GE Healthcare (US), Cognizant (US), athenahealth (US), SSI Group LLC (US), AdvantEdge Healthcare (US), and Huron Consulting Group (US)

Recent Developments:

  • In 2023, Optum partnered with Owensboro Health to manage revenue cycle and information technology and improve patient outcomes and safety.
  • In 2022, the R1 RCM announced 10-year end-to-end RCM partnerships with Scion Health, Sutter Health, and St. Clair Health to streamline workflow standardization and improve patient access platforms.
  • In 2022, McKesson signed a definitive agreement to acquire Rx Savings Solutions to offer medication therapy more affordable and increase medication adherence to improve outcomes.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=153900104

Revenue Cycle Management Market Advantages:

  • Improved Financial Performance: RCM solutions help healthcare organizations optimize their revenue streams by streamlining billing, coding, claims processing, and payment collection processes. By enhancing the accuracy and efficiency of these processes, RCM solutions minimize revenue leakage, reduce claim denials, and expedite payment cycles, leading to improved financial performance for healthcare providers.
  • Cost Savings: Implementing RCM solutions can result in significant cost savings for healthcare organizations. By automating manual tasks, reducing paperwork, and minimizing errors, RCM solutions reduce administrative expenses and enhance operational efficiency. Moreover, RCM solutions provide insights into billing patterns and revenue trends, enabling organizations to identify areas for improvement and implement proactive strategies to maximize revenue generation.
  • Enhanced Revenue Integrity: RCM solutions ensure the integrity of revenue by improving coding accuracy and compliance with regulatory requirements. With ever-changing healthcare regulations and reimbursement policies, RCM solutions help healthcare organizations stay up-to-date and compliant, reducing the risk of penalties and revenue loss due to non-compliance.
  • Increased Productivity: RCM solutions automate repetitive and time-consuming tasks, enabling healthcare professionals to focus on patient care rather than administrative burdens. By reducing manual intervention, RCM solutions streamline workflows, enhance productivity, and allow staff to allocate their time and expertise more effectively, leading to improved overall operational efficiency.
  • Real-time Analytics and Reporting: RCM solutions provide real-time data analytics and reporting capabilities, offering healthcare organizations valuable insights into key performance indicators, revenue trends, and financial metrics. These insights enable informed decision-making, identification of revenue optimization opportunities, and implementation of proactive strategies to address revenue cycle challenges.
  • Patient Satisfaction and Experience: RCM solutions contribute to improved patient satisfaction by enhancing the financial experience for patients. Transparent pricing, accurate cost estimates, and convenient payment options provided through RCM systems empower patients to make informed financial decisions and ease the burden of medical billing. This, in turn, enhances patient loyalty and contributes to a positive overall patient experience.
  • Scalability and Adaptability: RCM solutions can be tailored to the specific needs and size of healthcare organizations, making them scalable and adaptable. Whether it is a small clinic or a large hospital system, RCM solutions can accommodate varying volumes of transactions and adapt to evolving industry requirements, supporting the growth and changing needs of healthcare organizations.

In conclusion, the revenue cycle management market offers advantages such as improved financial performance, cost savings, enhanced revenue integrity, increased productivity, real-time analytics, patient satisfaction, and scalability. These advantages position RCM solutions as essential tools for healthcare organizations seeking to optimize revenue streams, improve operational efficiency, and provide an enhanced financial experience for patients.

Revenue Cycle Management Market – Report Highlights:

The global revenue cycle management market is projected to reach USD 84.15 billion by 2028 from USD 49.6 billion in 2023, at a CAGR of 11.1% during the forecast period. The market growth is majorly attributed to the need for increased patient volumes and the growing need to manage unstructured healthcare data. Also, growing regulatory requirements & government initiatives are expected to drive demand growth in the revenue cycle management market during the forecast period.

Recession Impact on Revenue cycle management market

Recession after Covid-19 did not have a substantial impact on the RCM market. In fact, according to industry experts, demand for RCM solutions increased to overcome the growing expenses and shortage of funds faced by healthcare providers. The highly efficient RCM solutions helped the healthcare providers to achieve their financial goals with the help of predictive analytics. However, few small healthcare practices shifted their economic focus to essential medical services due to budgetary constraints. This had affected the market growth to a certain extent.

R1 RCM (US), Oracle (US), and Optum (US) are among the significant providers of the Revenue cycle management market.  

Coverage of market players

We have covered 25 companies in the report, including R1 RCM (US), Oracle (US), Optum (US), McKesson Corporation (US), Change Healthcare (US), 3M (US),  AdvantEdge Healthcare (US), Conifer Health Solutions (US), Veradigm (US), GE Healthcare (US), Cognizant (US), Huron Consulting Group (US), SSI Group LLC (US), Experian plc (Ireland), and athenahealth (US).

Updated financial information and recent developments of the profiled players

The report contains the updated financial information for each listed public company from January 2021 to March 2023. It also includes the recent developments undertaken by market players as well as their strategic overview.

Recent developments help identify market trends and popular growth strategies market players adopt. The current analysis shows that service launches and acquisitions were prominent growth strategies for players between January 2020 and August 2022.

Market Overview and Industry Insights

Updated the market overview inclined to new recent developments and recently available statistics. Ecosystem/ market map, tariff, and regulatory landscape, case study analysis, key conferences & events in 2022-2023, Porter five forces analysis, adjacent market analysis, trends, key stakeholders and buying criteria, and indicative pricing analysis are added in industry insights.

Related Reports:

Patient Access Solutions Market – Global Forecasts to 2027

North American Healthcare IT Market – Global Forecasts to 2027

Medical Terminology Software Market – Global Forecasts to 2027

Population Health Management Market – Global Forecasts to 2027

Clinical Decision Support Systems Market – Global Forecasts to 2027

About MarketsandMarkets™:

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/revenue-cycle-management-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/revenue-cycle-management.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/revenue-cycle-management-market-worth-84-1-billion–marketsandmarkets-301867836.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024

Published

on

invitation-to-presentation-of-eqt-ab’s-q1-announcement-2024

STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826

The following files are available for download:

https://mb.cision.com/Main/87/3956826/2712771.pdf

Invitation to presentation of EQT AB’s Q1 Announcement 2024

https://news.cision.com/eqt/i/eqt-ab-group,c3285895

EQT AB Group

 

View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs

Published

on

kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs
  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Published

on

biovaxys-technology-corp.-provides-bi-weekly-mcto-status-update

VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html

Continue Reading

Trending